Exclusion Criteria:

- < 60 days of age (Refer to Febrile <u>Infant Clinical Pathway)</u>
- Concern for multisystem inflammatory syndrome (MIS-C) (Reference MIS-C)

Patient hospitalized for COVID-19 illness

What is the severity of illness?


High Risk of Progressing to Severe Disease

Regardless of COVID-19 immunization status ANY of the following:

- Age < 1 year
- Immunosuppressed
- Obesity: BMI ≥ 30 kg/m² or > 95th percentile for age/weight
- Medical complexity with respiratory technology dependence or impaired airway clearance
- · Persistent asthma or chronic lung disease, including lung disease associated with prematurity
- · Cardiac disease with cyanosis, pulmonary hypertension, or systolic dysfunction
- Sickle cell disease
- Uncontrolled diabetes mellitus

Mild-Moderate Illness

Not requiring supplemental oxygen (or no more than their baseline home O₂ needs)



Severe illness

Requiring supplemental oxygen (or more than their baseline home O₂ needs) or high-flow nasal cannula outside of intensive care

Is the clinical presentation consistent with bronchiolitis in otherwise healthy pt < 2 yrs? No **Contact Coagulation Services** Anticoagulation Clinical Pathway

Critical Illness

Requiring intensive care AND high-flow nasal cannula, non-invasive ventilation, mechanical ventilation, or ECMO

> Consult Coagulation Services and Infectious Diseases Anticoagulation Clinical Pathway

Medications (review medication precautions)

Remdesivir

There is not sufficient pediatric evidence on remdesivir in this scenario to provide a recommendation. Refer to remdesivir for children with COVID-19 and use shared decision making.

- Approved for pts ≥ 28 days AND ≥ 3 kg
- Within 7 days of symptom onset
- Duration: 3 days (If pt requires supplemental O₂ can extend to 5 days). Do not prolong stay for remdesivir.
- Dosing:
 - Day 1: 5 mg/kg IV (max dose 200 mg)
 - Day 2 3: 2.5 mg/kg IV daily (max dose 100 mg)

If remdesivir is not given:

- *Paxlovid:* (pt ≥ 12 years AND ≥ 40 kg)
 - Within 5 days of symptom onset
 - Duration: 5 days
 - Dosing:
 - Standard dose (eGFR ≥ 60 mL/min): nirmatrelvir 300 mg + ritonavir 100 mg PO
 - If eGFR 30 60 mL/min: nirmatrelvir 150 mg + ritonavir 100 mg PO BID

Medications (review medication precautions)

• Dexamethasone 0.15 mg/kg (max: 6 mg) PO/IV daily x 10 days or until discharge

AND

Remdesivir

- ∘ Approved for pts ≥ 28 days and ≥ 3 kg
- Within 7 days of symptoms onset
- Duration: 5 days. Do not prolong stay for remdesivir.
- Dosing:
 - Day 1: 5 mg/kg IV (max dose 200 mg)
- Days 2 5: 2.5 mg/kg IV daily (max dose 100 mg)

Medications (review medication precautions)

• Dexamethasone 0.15 mg/kg (max: 6 mg) PO/IV daily x 10 days or until discharge

AND

• *Tocilizumab* - Consider if patient is ≥ 2 years and not improving within 24 hrs of starting dexamethasone -

Single dose:

- 12 mg/kg for patients < 30 kg
- 8 mg/kg for patients ≥ 30 kg (max dose of 800 mg)

Remdesivir is not beneficial in critical illness

Provide supportive care until discharge



QR code for mobile view

Last Updated: 3.12.2025